The estimated Net Worth of Catherine Coste is at least $13.6 Тысяча dollars as of 26 January 2023. Ms. Coste owns over 2,190 units of Biomerica stock worth over $13,619 and over the last 4 years she sold BMRA stock worth over $0. In addition, she makes $0 as Independent Director at Biomerica.
Catherine has made over 2 trades of the Biomerica stock since 2020, according to the Form 4 filled with the SEC. Most recently she bought 2,190 units of BMRA stock worth $6,482 on 26 January 2023.
The largest trade she's ever made was buying 9,100 units of Biomerica stock on 26 October 2020 worth over $49,595. On average, Catherine trades about 2,258 units every 164 days since 2020. As of 26 January 2023 she still owns at least 43,790 units of Biomerica stock.
You can see the complete history of Ms. Coste stock trades at the bottom of the page.
Catherine Coste CPA serves as Independent Director of the Company. Ms. Coste recently retired from Deloitte and Touche, where she was a senior partner and served as Deloitte’s Life Sciences Industry Executive Leader. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has extensive public company Board experience, often attending multiple Board Committee meetings per month. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls and corporate governance. Ms. Coste is a Certified Public Accountant.
Catherine Coste is 54, she's been the Independent Director of Biomerica since 2020. There are 7 older and 2 younger executives at Biomerica. The oldest executive at Biomerica Inc. is Francis Cano, 76, who is the Independent Director.
Over the last 12 years, insiders at Biomerica have traded over $80,900 worth of Biomerica stock and bought 151,277 units worth $334,788 . The most active insiders traders include Mark A Sirgo, David Moatazedi и John P. Kenny. On average, Biomerica executives and independent directors trade stock every 61 days with the average trade being worth of $3,349. The most recent stock trade was executed by Zackary S. Irani on 25 May 2023, trading 700 units of BMRA stock currently worth $1,113.
biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh
Biomerica executives and other stock owners filed with the SEC include: